Search alternatives:
nm decrease » nn decrease (Expand Search), _ decrease (Expand Search), gy decreased (Expand Search)
ng decrease » nn decrease (Expand Search), _ decrease (Expand Search), gy decreased (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), mean decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
40 nm » 10 nm (Expand Search), 20 nm (Expand Search), 4 nm (Expand Search)
50 a » 50 μ (Expand Search), 50 _ (Expand Search), 50 c (Expand Search)
nm decrease » nn decrease (Expand Search), _ decrease (Expand Search), gy decreased (Expand Search)
ng decrease » nn decrease (Expand Search), _ decrease (Expand Search), gy decreased (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), mean decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
40 nm » 10 nm (Expand Search), 20 nm (Expand Search), 4 nm (Expand Search)
50 a » 50 μ (Expand Search), 50 _ (Expand Search), 50 c (Expand Search)
-
161
-
162
-
163
-
164
-
165
-
166
Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma
Published 2024“…In our previous study, we have identified a series of type I PRMT inhibitors, among which ZL-28-6 (<b>6</b>) exhibited increased activity against CARM1 while displaying decreased potency against other type I PRMTs. …”
-
167
Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma
Published 2024“…In our previous study, we have identified a series of type I PRMT inhibitors, among which ZL-28-6 (<b>6</b>) exhibited increased activity against CARM1 while displaying decreased potency against other type I PRMTs. …”
-
168
Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma
Published 2024“…In our previous study, we have identified a series of type I PRMT inhibitors, among which ZL-28-6 (<b>6</b>) exhibited increased activity against CARM1 while displaying decreased potency against other type I PRMTs. …”
-
169
First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation
Published 2022“…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC<sub>50</sub> value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC<sub>0‑inf</sub> (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …”
-
170
First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation
Published 2022“…Representative inhibitor <b>35m</b> exhibits potent HDAC6 inhibitory activity with an IC<sub>50</sub> value of 0.019 μM. To our surprise, <b>35m</b> establishes significant improvement in the pharmacokinetic property with much higher AUC<sub>0‑inf</sub> (10292 ng·h/mL) and oral bioavailability (93.4%) than hydroximic acid-based HDAC6 inhibitors Tubastatin A and ACY-1215. …”
-
171
-
172
-
173
Transforming Small-Molecule Nanoaggregation into Functional Drug Delivery Platforms
Published 2025“…The IC<sub>50</sub> value of <b>Nano-CC1-Acl</b> further decreases to 0.20 ± 0.16 μM in the presence of cysteine, a biothiol. …”
-
174
Transforming Small-Molecule Nanoaggregation into Functional Drug Delivery Platforms
Published 2025“…The IC<sub>50</sub> value of <b>Nano-CC1-Acl</b> further decreases to 0.20 ± 0.16 μM in the presence of cysteine, a biothiol. …”
-
175
-
176
-
177
-
178
-
179
-
180